Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Cancer Research

• Publication date

  2010-02-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-09-2546PMID 20179235
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [EAU guidelines on prostate cancer].

  2009cited by this paper
• [Role of lymph node dissection in prostate cancer].

  2009cited by this paper
• Stellenwert der Lymphadenektomie beim Prostatakarzinom

  2008cited by this paper
• HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.

  2008cited by this paper
• Prognostic value of Her‐2/neu and DNA index for progression, metastasis and prostate cancer‐specific death in men with long‐term follow‐up after radical prostatectomy

  2008cited by this paper
• [Prostate carcinoma].

  2008cited by this paper
• Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients

  2008cited by this paper
• Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms

  2007cited by this paper
• Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

  2005cited by this paper
• A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

  2005cited by this paper
• Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

  2005cited by this paper
• The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial

  2004cited by this paper
• Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer

  2004cited by this paper
• HER2 and COX2 expression in human prostate cancer.

  2004cited by this paper
• Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinoma

  2004cited by this paper
• Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers

  2003cited by this paper
• Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone.

  2002cited by this paper
• Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.

  2002cited by this paper
• Independent prognostic significance of HER‐2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy

  2002cited by this paper
• Her2 expression in prostatic cancer: a comparison with mammary carcinoma.

  2002cited by this paper
• Evaluation of HER‐2/neu expression in prostatic adenocarcinoma

  2002cited by this paper
• HER‐2 profiling and targeting in prostate carcinoma

  2002cited by this paper
• Tissue microarrays for rapid linking of molecular changes to clinical endpoints.

  2001cited by this paper
• Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.

  2001cited by this paper
• EAU Guidelines on Prostate Cancer

  2001cited by this paper
• HER2 protein expression and gene amplification in androgen-independent prostate cancer.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001influential reference
• Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade

  2001cited by this paper
• Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease.

  2001cited by this paper
• HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.

  2001cited by this paper
• Her-2-neu expression and progression toward androgen independence in human prostate cancer.

  2000cited by this paper
• Global analysis of differential gene expression between prostate cancer and normal prostate tissues using cDNA microarray of open-reading frame expressed sequence tags (ORESTES)

  2000cited by this paper
• Prognostic value of immunohistochemical expression of the c‐erbB‐2 oncoprotein in metastasic prostate cancer

  1999cited by this paper
• Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.

  1999cited by this paper
• A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

  1999cited by this paper
• Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.

  1999cited by this paper
• Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers.

  1999cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.

  1997cited by this paper
• Prognostic significance of HER‐2/neu gene amplification status by fluorescence in Situ hybridization of prostate carcinoma

  1997cited by this paper
• Overexpression of her-2/neu in human prostate cancer and benign hyperplasia.

  1996cited by this paper
• Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer

  1995cited by this paper
• Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma.

  1993cited by this paper
• Contribution of HER‐2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis

  1993cited by this paper
• Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas.

  1992cited by this paper
• Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues.

  1992cited by this paper
• p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate.

  1992cited by this paper
• Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate.

  1991cited by this paper
• Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

  1990cited by this paper
• c‐erbB‐2 oncoprotein expression in primary human tumors

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• Predicting HER2 overexpression in prostate cancer using machine learning: implications for personalized therapy

  2026cites this paper
• Historical Perspective of HER2 Testing and Treatment in Prostate Cancer.

  2026influential citation
• Localized high-risk prostate cancer harbors an androgen receptor activity–low subpopulation susceptible to HER2 inhibition

  2025cites this paper
• HER2 as a molecular trojan horse in prostate cancer: mechanistic insights and therapeutic unlocks

  2025influential citation
• Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies

  2025cites this paper
• Human Epidermal Growth Factor Receptor 2 [HER‐2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran

  2025cites this paper
• The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer

  2025cites this paper
• Evaluation of HER2 expression in prostate cancer among Mexican patients.

  2025cites this paper
• Clinical Response to Novel Combination of Trastuzumab Deruxtecan and Abiraterone in HER2-Expressing Metastatic Castration-Resistant Prostate Cancer.

  2025cites this paper
• Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition

  2024cites this paper
• Comparison of molecular analysis results determined by next-generation sequencing to immunohistochemical indicators and clinicopathological parameters in prostate adenocarcinomas.

  2024cites this paper
• Feasibility study of ADCs targeting TROP-2, HER2, and CD46 in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate

  2024cites this paper
• Amiloride Sensitizes Prostate Cancer Cells to the Reversible Tyrosine Kinase Inhibitor Lapatinib by Modulating ERBB3 Subcellular Localization

  2024cites this paper
• Response of Human Epidermal Growth Factor Receptor 2–Expressing Prostate Cancer to Trastuzumab Deruxtecan

  2024cites this paper
• Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas

  2024influential citation
• Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics

  2024cites this paper
• The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma.

  2023cites this paper
• CAR-NK cell therapy for glioblastoma: what to do next?

  2023cites this paper
• Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?

  2023cites this paper
• HER2 as a potential therapeutic target on quiescent prostate cancer cells

  2023cites this paper
• Unravelling the Role of Kinases That Underpin Androgen Signalling in Prostate Cancer

  2022cites this paper
• Study of HER2/neu over Expression and Androgen Receptor Status in Prostate Neoplasm-Correlating with Histological Grading

  2021cites this paper
• The influence of testosterone suppression on HER2 immunoexpression in prostatic neoplastic tissue

  2021cites this paper
• Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

  2021cites this paper
• Amplification of the human epidermal growth factor receptor 2 (HER2) gene is associated with a microsatellite stable status in Chinese gastric cancer patients.

  2021cites this paper
• Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality

  2021cites this paper
• Deletion of 2q21 Characterizes a Small Subgroup of Aggressive ERGNegative Prostate Cancers

  2021cites this paper
• Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets

  2021cites this paper
• High RSF1 protein expression is an independent prognostic feature in prostate cancer

  2020cites this paper
• Icaritin reduces prostate cancer progression via inhibiting high-fat diet-induced serum adipokine in TRAMP mice model

  2020cites this paper
• KRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literature

  2020cites this paper
• High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer.

  2020cites this paper
• Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.

  2020cites this paper
• Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer

  2020cites this paper
• Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients

  2020cites this paper
• Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion

  2020cites this paper
• Microenvironment-Mediated Resistance to Anti-Androgen Therapy.

  2020cites this paper
• ErbB-2 signaling in advanced prostate cancer progression and potential therapy

  2019cites this paper
• The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer

  2019cites this paper
• Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer

  2019cites this paper
• Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase

  2019cites this paper
• A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer

  2019cites this paper
• Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion

  2019cites this paper
• Upregulation of SPDEF is associated with poor prognosis in prostate cancer

  2019cites this paper
• Expression of HER Receptor Proteins in Prostate Adenocarcinoma: A Perspective from North Central Nigeria

  2019cites this paper
• Detection of a prostate cancer cell line using a bioluminescent affiprobe: An attempt to develop a new molecular probe for ex vivo studies.

  2019cites this paper
• High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer

  2019cites this paper
• Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2‐expressing tumours

  2019cites this paper
• CMTM5表达对多发性骨髓瘤细胞增殖的影响及其机制研究

  2019cites this paper
• PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer

  2018cites this paper
• Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/β-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer

  2018cites this paper
• High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer

  2018cites this paper
• Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.

  2017cites this paper
• βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.

  2017cites this paper
• HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone.

  2017influential citation
• p16 upregulation is linked to poor prognosis in ERG negative prostate cancer

  2016cites this paper
• Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis

  2016cites this paper
• Antitumoral action of icaritin in LNCaP prostate cancer cells by regulating PEA3/HER2/AR signaling

  2016cites this paper
• Plexin-B1 signalling promotes androgen receptor translocation to the nucleus

  2016cites this paper
• Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer

  2016cites this paper
• Bedeutung und Charakterisierung der 6q-Deletion beim Prostatakarzinom

  2016influential citation
• Does the molecular classification of breast cancer point the way for biomarker identification in prostate cancer

  2016cites this paper
• Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer

  2015cites this paper
• The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion

  2015cites this paper
• HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.

  2015cites this paper
• Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.

  2015cites this paper
• Moderate HER 2 expression as a prognostic factor in hormone receptor positive breast cancer

  2015cites this paper
• ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.

  2015cites this paper
• Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer

  2015cites this paper
• HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy

  2015cites this paper
• Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer

  2015cites this paper
• Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.

  2015cites this paper
• HER-2-based design of pertuzumab mimetic peptides

  2015cites this paper
• High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer

  2015cites this paper
• Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer

  2015cites this paper
• Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade

  2015cites this paper
• Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.

  2015cites this paper
• Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer

  2015cites this paper
• Potential Upstream Regulators of Cannabinoid Receptor 1 Signaling in Prostate Cancer: A Bayesian Network Analysis of Data From a Tissue Microarray

  2014cites this paper
• βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.

  2014cites this paper
• Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer

  2014cites this paper
• Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment

  2014cites this paper
• Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer

  2014influential citation
• Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients

  2014cites this paper
• Prostate cancer relevant antigens and enzymes for targeted drug delivery.

  2014cites this paper
• Circulating Her-2/Neu Extracellular Domain in Breast Cancer Patients-Correlation with Prognosis and Clinicopathological Parameters Including Steroid Receptor, Her-2/Neu Receptor Coexpression

  2014cites this paper
• Single compartment drug delivery.

  2014cites this paper
• HER2 aberrations in cancer: implications for therapy.

  2014cites this paper
• In vitro modeling of HER2-targeting therapy in disseminated prostate cancer.

  2014influential citation
• ErbB2 Receptor Immunoreactivity in Prostate Cancer: Relationship to the Androgen Receptor, Disease Severity at Diagnosis and Disease Outcome

  2014influential citation
• Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy

  2014cites this paper
• The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells

  2014cites this paper
• Loss of Somatostatin Receptor Subtype 2 in Prostate Cancer Is Linked to an Aggressive Cancer Phenotype, High Tumor Cell Proliferation and Predicts Early Metastatic and Biochemical Relapse

  2014cites this paper
• Prognostische und prädiktive molekulare Marker urologischer Tumoren

  2014cites this paper
• Engineering antibodies to study and improve immunomagnetic isolation of tumour cells

  2013cites this paper
• Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment

  2013cites this paper
• Molecular Markers for Prostate Cancer in Formalin-Fixed Paraffin-Embedded Tissues

  2013cites this paper
• Loss of pSer2448‐mTOR expression is linked to adverse prognosis and tumor progression in ERG‐fusion‐positive cancers

  2013cites this paper
• Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis

  2013cites this paper
• Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions

  2013cites this paper